Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchial Asthma
Conditions
Bronchial Asthma
Trial Timeline
Oct 17, 2018 → Mar 31, 2020
NCT ID
NCT03394989About Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT is a phase 3 stage product being developed by Cipla for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT03394989. Target conditions include Bronchial Asthma.
What happened to similar drugs?
3 of 15 similar drugs in Bronchial Asthma were approved
Approved (3) Terminated (3) Active (9)
❌Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3
🔄Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerGlenmark PharmaceuticalsPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03394989 | Phase 3 | Completed |
Competing Products
20 competing products in Bronchial Asthma